Joint Formulary & PAD

Metformin hydrochloride/vildagliptin - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

Sitagliptin is the preferred DPP4. Reserve combination products for patients in whom separate components are less appropriate. Existing patients would not be expected to change therapy unless appropriate to do so.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Metformin hydrochloride/vildagliptin
Indication :
Diabetes Mellitus
Group Name :
Keywords :
Gliptins, DPP-4, Dipeptylpeptidase -4 inhibitor, Type II
Brand Names Include :
Eucreas
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Metformin hydrochloride/vildagliptin is used to treat.

  • No records returned.

Committee Recommendations (0)

  • No records returned.